Fourth Quarter 2019 Highlights:
- Total revenue, including royalty and other revenue, was $247.5
million;
- Product revenue increased 11.8% to $247.4 million, or 12.0% on
a constant currency basis;
- GAAP net income per diluted share was $0.92; and
- Non-GAAP net income per diluted share was $0.91.
Full-Year 2019 Highlights:
- Total revenue, including royalty and other revenue, was $937.8
million;
- Product revenue increased 12.8% to $936.4 million, or 13.6% on
a constant currency basis;
- GAAP net income per diluted share of $3.44; and
- Non-GAAP net income per diluted share was $3.22.
Masimo (Nasdaq: MASI) today announced its financial results for
the fourth quarter and full-year ended December 28, 2019.
Fourth Quarter 2019 Results:
Total revenue, including royalty and other revenue, was $247.5
million. Product revenues increased 11.8% to $247.4 million, or
12.0% on a constant currency basis. Shipments of noninvasive
technology boards and monitors increased 1.8% to 61,400 in the
fourth quarter of 2019, compared to 60,300 in the fourth quarter of
2018.
Fourth quarter 2019 GAAP operating margin was 24.9%, compared to
24.2% in the prior year period. Fourth quarter 2019 non-GAAP
operating margin was 25.7%, compared to 23.8% in the prior year
period.
For the fourth quarter of 2019, GAAP net income was $52.9
million, or $0.92 per diluted share. Non-GAAP net income was $52.1
million, or $0.91 per diluted share.
Full-Year 2019 Results:
Total revenue, including royalty and other revenue, was $937.8
million. Product revenue increased 12.8% to $936.4 million, or
13.6% on a constant currency basis. Shipments of noninvasive
technology boards and monitors increased 6.3% to 246,200 for the
full-year 2019, compared to 231,700 for the full-year 2018.
Full-year 2019 GAAP operating margin was 23.6%, compared to
24.2% in the prior year period. Full-year 2019 non-GAAP operating
margin was 24.0%, compared to 22.0% in the prior year period.
For the full-year of 2019, GAAP net income was $196.2 million,
or $3.44 per diluted share. Non-GAAP net income was $183.9 million,
or $3.22 per diluted share.
Total cash, cash equivalents and short term investments
increased $135.2 million during the year to $687.7 million as of
December 28, 2019.
Joe Kiani, Chairman and Chief Executive Officer of Masimo, said,
“In 2019, we advanced our mission to improve patient outcomes while
reducing the cost of care. To mark our 30th anniversary, we
delivered a new product to care providers in every month of 2019,
while we also grew our product revenue 12.8%, or 13.6% on a
constant currency basis. We once again delivered above market
growth and improved our non-GAAP operating margins by 200 basis
points through disciplined execution of our strategy. For 2020, we
are projecting product revenues of $1.035 billion, GAAP earnings
per share of $3.64 and non-GAAP earnings per share of $3.56.”
2020 Financial Guidance
The Company provided the following estimates for its full-year
2020 guidance:
(in millions, except percentages and
earnings per share)
2020
Updated Guidance(1)
GAAP
Non-GAAP
Total revenue, including royalty and other
revenue
$
1,035
$
1,035
Product revenue
$
1,035
$
1,035
Percentage growth - as reported
10.5
%
N/A
Percentage growth - constant currency
N/A
11.0
%
Royalty and other revenue
$
—
$
—
Gross margin
67.7
%
68.0
%
Operating margin
24.0
%
24.7
%
Earnings per diluted share
$
3.64
$
3.56
Estimated tax rate
19.1
%
23.3
%
______________ (1) Consistent with prior
guidance provided on January 14, 2020.
- Product revenue of $1.035 billion, which reflects growth of
10.5% and constant currency growth of 11.0%;
- GAAP earnings per diluted share of $3.64;
- Non-GAAP earnings per diluted share of $3.56;
- Included in our full-year 2020 revenue guidance is
approximately $4 million of year-over-year currency headwinds.
Supplementary Non-GAAP Financial Information
For additional non-GAAP financial details, please visit the
Investor Relations section of the Company’s website at www.masimo.com to access Supplementary Financial
Information.
Non-GAAP Financial Measures
The non-GAAP financial measures contained herein are a
supplement to the corresponding financial measures prepared in
accordance with U.S. GAAP. The non-GAAP financial measures
presented exclude the items described below. Management believes
that adjustments for these items assist investors in making
comparisons of period-to-period operating results. Furthermore,
management also believes that these items are not indicative of the
Company’s on-going core operating performance. These non-GAAP
financial measures have certain limitations in that they do not
reflect all of the costs associated with the operations of the
Company’s business as determined in accordance with GAAP.
Therefore, investors should consider non-GAAP financial measures
in addition to, and not as a substitute for, or as superior to,
measures of financial performance prepared in accordance with GAAP.
The non-GAAP financial measures presented by the Company may be
different from the non-GAAP financial measures used by other
companies.
The Company has presented the following non-GAAP measures to
assist investors in understanding the Company’s core net operating
results on an on-going basis: (i) constant currency product revenue
growth %, (ii) non-GAAP net income, (iii) non-GAAP earnings per
diluted share, (iv) non-GAAP gross profit/margin and (v) non-GAAP
operating income/margin. These non-GAAP financial measures may also
assist investors in making comparisons of the Company’s core
operating results with those of other companies. Management
believes constant currency product revenue growth, non-GAAP gross
profit/margin, non-GAAP operating income/margin, non-GAAP net
income and non-GAAP earnings per diluted share are important
measures in the evaluation of the Company’s performance and uses
these measures to better understand and evaluate our business.
The non-GAAP financial measures reflect adjustments for the
following items, as well as the related income tax effects
thereof:
Constant currency adjustments.
Some of our sales agreements with foreign customers provide for
payment in currencies other than the U.S. Dollar. These foreign
currency revenues, when converted into U.S. Dollars, can vary
significantly from period to period depending on the average and
quarter-end exchange rates during a respective period. We believe
that comparing these foreign currency denominated revenues by
holding the exchange rates constant with the prior year period is
useful to management and investors in evaluating our product
revenue growth rates on a period-to-period basis. We anticipate
that fluctuations in foreign exchange rates and the related
constant currency adjustments for calculation of our product
revenue growth rate will continue to occur in future periods.
Royalty and other revenue, net of related
costs.
We derive royalty and other revenue, net of related costs, from
certain non-recurring contractual arrangements that we do not
expect to continue in the future. We believe the exclusion of
royalty and other revenue, net of related costs, associated with
these non-recurring revenue streams is useful to management and
investors in evaluating the performance of our ongoing operations
on a period-to-period basis.
Acquisition-related costs, including
depreciation and amortization.
In the event the Company acquires, invests in or divests certain
business operations, there may be non-recurring gains, losses or
expenses that will be recognized related to the assets and/or
liabilities sold or acquired that are not representative of normal
on-going cash flows. Furthermore, there may be depreciation and
amortization related to the revaluation of assets and liabilities
(primarily intangible assets, property, plant and equipment
adjustments, inventory revaluation, lease liabilities, etc.) to
fair value through purchase accounting related to value created by
the seller prior to the acquisition/strategic investment that does
not reflect the normal on-going costs of operating our core
business. We believe that exclusion of these gains, losses or costs
in presenting non-GAAP financial measures provides management and
investors a more effective means of evaluating historical
performance and projected costs and the potential for realizing
cost efficiencies within our core business. Depreciation and
amortization related to the revaluation of acquisition related
assets and liabilities will generally recur in future periods.
Litigation damages, awards and
settlements
In connection with litigation proceedings arising in the course
of our business, we have recorded expenses as a defendant in such
proceedings in the form of damages, as well as gains as a plaintiff
in such proceedings in the form of litigation awards and settlement
proceeds. We believe that exclusion of these gains (net of any
related costs incurred in the period the award or settlement is
recognized) and losses is useful to management and investors in
evaluating the performance of our ongoing operations on a
period-to-period basis. In this regard, we note that these expenses
and gains are generally unrelated to our core business and/or
infrequent in nature.
Realized and unrealized gains or losses
from foreign currency transactions.
We are exposed to foreign currency gains or losses on
outstanding foreign currency denominated receivables and payables
related to certain customer sales agreements, product costs and
other operating expenses. As the Company does not actively hedge
these currency exposures, changes in the underlying currency rates
relative to the U.S. Dollar may result in realized and unrealized
foreign currency gains and losses between the time these
receivables and payables arise and the time that they are settled
in cash. Since such realized and unrealized foreign currency gains
and losses are the result of macro-economic factors and can vary
significantly from one period to the next, we believe that
exclusion of such realized and unrealized gains and losses are
useful to management and investors in evaluating the performance of
our ongoing operations on a period-to-period basis. Realized and
unrealized foreign currency gains and losses are likely to recur in
future periods.
Excess tax benefits from stock-based
compensation.
Current authoritative accounting guidance requires that excess
tax benefits or costs recognized on stock-based compensation
expense be reflected in our provision for income taxes rather than
paid-in capital. Since we cannot control or predict when stock
option awards will be exercised or the price at which such awards
will be exercised, the impact of such guidance can create
significant volatility in our effective tax rate from one period to
the next. We believe that exclusion of these excess tax benefits or
costs is useful to management and investors in evaluating the
performance of our ongoing operations on a period-to-period basis.
These excess tax benefits or costs will generally recur in future
periods as long as we continue to issue equity awards to our
employees.
Tax impacts that may not be representative
of the ongoing results of our core operations.
From time-to-time, we may experience significant non-recurring
tax events, such as changes in tax laws and regulations or the
derecognition of uncertain tax positions related to non-recurring
transactions due to the expiration of the statutes of limitations.
We believe that exclusion of such tax charges or benefits is useful
to management and investors in evaluating the performance of our
ongoing operations on a period-to-period basis. In this regard, we
note that these tax items are unrelated to our core business and
generally unique and non-recurring in nature.
Fourth Quarter and Full-Year 2019 Actuals
versus Fourth Quarter 2018 and Full-Year Actuals:
RECONCILIATION OF GAAP TO CONSTANT CURRENCY PRODUCT
REVENUE(1):
Quarter Ended
(in thousands, except
percentages)
December 28, 2019
December 29, 2018
GAAP product revenue
$
247,434
$
221,413
Non-GAAP constant currency
adjustments:
Constant currency F/X adjustments
571
—
Total non-GAAP product revenue
adjustments
571
—
Constant currency product revenue
$
248,005
$
221,413
Product revenue growth %:
GAAP
11.8
%
Constant currency
12.0
%
______________ (1) May not foot due to
rounding.
RECONCILIATION OF GAAP TO CONSTANT CURRENCY PRODUCT
REVENUE(1):
Year Ended
(in thousands, except
percentages)
December 28, 2019
December 29, 2018
GAAP product revenue
$
936,408
$
829,874
Non-GAAP constant currency
adjustments:
Constant currency F/X adjustments
6,702
—
Total non-GAAP product revenue
adjustments
6,702
—
Constant currency product revenue
$
943,110
$
829,874
Product revenue growth %:
GAAP
12.8
%
Constant currency
13.6
%
______________(1) May not foot due to rounding.
RECONCILIATION OF GAAP TO NON-GAAP NET INCOME AND NET
INCOME PER DILUTED SHARE(1):
Quarter Ended
December 28, 2019
December 29, 2018
(in thousands, except earnings per
share)
$
Per Diluted Share
$
Per Diluted Share
GAAP net income
$
52,921
$
0.92
$
46,934
$
0.83
Non-GAAP adjustments:
Royalty and other revenue, net of related
costs
(45
)
—
(1,535
)
(0.03
)
Acquisition/strategic investment related
costs
2,135
0.04
361
0.01
Litigation damages, awards and
settlements
—
—
(75
)
—
Non-operating other (income) expense
312
0.01
1,263
0.02
Tax impact of pre-tax non-GAAP adjustments
above
(566
)
(0.01
)
(513
)
(0.01
)
Excess tax benefits from stock-based
compensation
(2,631
)
(0.05
)
(294
)
(0.01
)
2017 U.S. Tax Reform
—
—
(675
)
(0.01
)
Total non-GAAP adjustments
(796
)
(0.01
)
(1,468
)
(0.03
)
Non-GAAP net income
$
52,126
$
0.91
$
45,465
$
0.81
Weighted average shares
outstanding-diluted
57,267
56,449
______________ (1) May not foot due to
rounding.
RECONCILIATION OF GAAP TO NON-GAAP NET INCOME AND NET
INCOME PER DILUTED SHARE(1):
Year Ended
December 28, 2019
December 29, 2018
(in thousands, except earnings per
share)
$
Per Diluted Share
$
Per Diluted Share
GAAP net income
$
196,216
$
3.44
$
193,543
$
3.45
Non-GAAP adjustments:
Royalty and other revenue, net of related
costs
(1,262
)
(0.02
)
(27,704
)
(0.49
)
Acquisition/strategic investment related
costs
4,729
0.08
1,442
0.03
Litigation damages, awards and
settlements
—
—
425
0.01
Non-operating other (income) expense
627
0.01
2,027
0.04
Tax impact of pre-tax non-GAAP adjustments
above
(689
)
(0.01
)
5,532
0.10
Excess tax benefits from stock-based
compensation
(15,692
)
(0.27
)
(22,036
)
(0.39
)
Tax impact of expiration of certain
statutes of limitations related to unique and non-recurring tax
positions
—
—
(4,169
)
(0.07
)
2017 U.S. Tax Reform
—
—
(675
)
(0.01
)
Total non-GAAP adjustments
(12,286
)
(0.22
)
(45,157
)
(0.81
)
Non-GAAP net income
$
183,930
$
3.22
$
148,385
$
2.65
Weighted average shares
outstanding-diluted
57,100
56,039
______________ (1) May not foot due to
rounding.
RECONCILIATION OF GAAP TO NON-GAAP OPERATING
INCOME/MARGIN %(1):
Quarter Ended
December 28, 2019
December 29, 2018
(in thousands, except
percentages)
$
$
GAAP operating income/margin
$
61,557
$
53,906
Non-GAAP adjustments:
Royalty and other revenue, net of related
costs
(45
)
(1,535
)
Acquisition/strategic investment related
costs
2,135
361
Litigation damages, awards and
settlements
—
(75
)
Total non-GAAP adjustments
2,090
(1,250
)
Non-GAAP operating income/margin
$
63,647
$
52,655
GAAP operating income/margin %
24.9
%
24.2
%
Non-GAAP operating income/margin %
25.7
%
23.8
%
______________(1) May not foot due to rounding.
RECONCILIATION OF GAAP OPERATING INCOME/MARGIN
%(1):
Year Ended
December 28, 2019
December 29, 2018
(in thousands, except
percentages)
$
$
GAAP operating income/margin
$
221,216
$
208,044
Non-GAAP adjustments to product operating
income/margin:
Royalty and other revenue, net of related
costs
(1,262
)
(27,704
)
Acquisition/strategic investment related
costs
4,729
1,442
Litigation damages, awards and
settlements
—
425
Total non-GAAP adjustments
3,467
(25,837
)
Non-GAAP operating income/margin
$
224,683
$
182,206
GAAP operating income/margin %
23.6
%
24.2
%
Non-GAAP operating income/margin %
24.0
%
22.0
%
______________(1) May not foot due to rounding.
Full-Year 2020 Guidance versus Full-Year
2019 Actuals:
RECONCILIATION OF GAAP PRODUCT
REVENUE GROWTH % TO CONSTANT CURRENCY PRODUCT REVENUE GROWTH
%(1):
Full-Year 2020 Updated
Guidance(2)
Full-Year 2019 Actuals
GAAP product revenue
$
1,035,000
$
936,408
Non-GAAP constant currency
adjustments:
Constant currency F/X adjustments
4,000
—
Total non-GAAP constant currency
adjustments
4,000
—
Non-GAAP constant currency product
revenue
$
1,039,000
$
936,408
Product revenue growth %:
GAAP
10.5
%
Non-GAAP constant currency
11.0
%
________________
(1) May not foot due to rounding.
(2) Consistent with prior guidance
provided on January 14, 2020.
RECONCILIATION OF GAAP TO NON-GAAP NET INCOME AND NET
INCOME PER DILUTED SHARE(1):
Full-Year 2020
Guidance(2)
Full-Year 2019 Actuals
(in thousands, except earnings per
share)
$
Per Diluted Share
$
Per Diluted Share
GAAP net income
$
210,500
$
3.64
$
196,216
$
3.44
Non-GAAP net income adjustments:
Royalty and other revenue, net of related
costs
—
—
(1,262
)
(0.02
)
Acquisition/strategic investment related
costs
8,000
0.14
4,729
0.08
Non-operating other (income) expense
—
—
627
0.01
Tax impact of pre-tax non-GAAP adjustments
above
(1,900
)
(0.03
)
(689
)
(0.01
)
Excess tax benefits from stock-based
compensation
(11,000
)
(0.19
)
(15,692
)
(0.27
)
Total non-GAAP adjustments
(4,900
)
(0.08
)
(12,286
)
(0.22
)
Non-GAAP net income
$
205,600
$
3.56
$
183,930
$
3.22
Weighted average shares
outstanding-diluted
57,800
57,100
________________ (1) May not foot due to
rounding. (2) Consistent with prior guidance provided on January
14, 2020.
RECONCILIATION OF GAAP TO NON-GAAP GROSS PROFIT/MARGIN
AND OPERATING INCOME/MARGIN(1):
Full-Year 2020
Guidance(2)
Full-Year 2019 Actuals
(in thousands, except earnings per
share)
GAAP gross profit/margin
$
700,400
$
629,172
Non-GAAP adjustments:
Royalty and other revenue, net of related
costs
—
(1,262
)
Acquisition/strategic investment related
costs
3,000
511
Total non-GAAP adjustments
3,000
(751
)
Non-GAAP gross profit/margin
$
703,400
$
628,421
GAAP gross profit/margin %
67.7
%
67.1
%
Non-GAAP gross profit/margin %
68.0
%
67.1
%
GAAP operating income/margin
$
248,000
$
221,216
Non-GAAP adjustments:
Royalty and other revenue, net of related
costs
—
(1,262
)
Acquisition/strategic investment related
costs
8,000
4,729
Litigation damages, awards and
settlements
—
—
Total non-GAAP adjustments
8,000
3,467
Non-GAAP operating income/margin
$
256,000
$
224,683
GAAP operating income/margin %
24.0
%
23.6
%
Non-GAAP operating income/margin %
24.7
%
24.0
%
________________(1) May not foot due to rounding.(2) Consistent
with prior guidance provided on January 14, 2020.
Conference Call
The conference call to review Masimo’s complete financial
results for the fourth quarter and full-year ended December 28,
2019 will begin at 1:30 p.m. PT (4:30 p.m. ET) on February 19, 2020
and will be hosted by Joe Kiani, Chairman and Chief Executive
Officer, and Micah Young, Executive Vice President and Chief
Financial Officer. A live webcast of the conference call will be
available online from the investor relations page of the Company’s
corporate website at www.masimo.com.
The dial-in numbers are (833) 227-5837 for domestic callers and
+1 (825) 312-2251 for international callers. The reservation code
for both dial-in numbers is 2862927. After the live webcast, the
call will be available on Masimo’s website through March 19, 2020.
In addition, a telephonic replay of the call will be available
through March 4, 2020. The replay dial-in numbers are (800)
585-8367 for domestic callers and +1 (416) 621-4642 for
international callers. Please use reservation code 2862927 .
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company
that develops and produces a wide array of industry-leading
monitoring technologies, including innovative measurements,
sensors, patient monitors, and automation and connectivity
solutions. Our mission is to improve patient outcomes and reduce
the cost of care. Masimo SET® Measure-through Motion and Low
Perfusion™ pulse oximetry, introduced in 1995, has been shown in
over 100 independent and objective studies to outperform other
pulse oximetry technologies.1 Masimo SET® has also been shown to
help clinicians reduce severe retinopathy of prematurity in
neonates,2 improve CCHD screening in newborns,3 and, when used for
continuous monitoring with Masimo Patient SafetyNet™ in
post-surgical wards, reduce rapid response team activations, ICU
transfers, and costs.4-6 Masimo SET® is estimated to be used on
more than 100 million patients in leading hospitals and other
healthcare settings around the world,7 and is the primary pulse
oximetry at 9 of the top 10 hospitals according to the 2019-20 U.S.
News and World Report Best Hospitals Honor Roll.8 Masimo continues
to refine SET® and in 2018, announced that SpO2 accuracy on RD SET®
sensors during conditions of motion has been significantly
improved, providing clinicians with even greater confidence that
the SpO2 values they rely on accurately reflect a patient’s
physiological status. In 2005, Masimo introduced rainbow® Pulse
CO-Oximetry technology, allowing noninvasive and continuous
monitoring of blood constituents that previously could only be
measured invasively, including total hemoglobin (SpHb®), oxygen
content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®),
Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen
Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient
Monitoring and Connectivity Platform, built from the ground up to
be as flexible and expandable as possible to facilitate the
addition of other Masimo and third-party monitoring technologies;
key Masimo additions include Next Generation SedLine® Brain
Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography
with NomoLine® sampling lines. Masimo’s family of continuous and
spot-check monitoring Pulse CO-Oximeters® includes devices designed
for use in a variety of clinical and non-clinical scenarios,
including tetherless, wearable technology, such as Radius-7® and
Radius PPG™, portable devices like Rad-67™, fingertip pulse
oximeters like MightySat® Rx, and devices available for use both in
the hospital and at home, such as Rad-97®. Masimo hospital
automation and connectivity solutions are centered around the Iris®
platform, and include Iris Gateway®, Patient SafetyNet, Replica™,
Halo ION™, UniView™, and Doctella™. Additional information about
Masimo and its products may be found at www.masimo.com. Published
clinical studies on Masimo products can be found at
www.masimo.com/evidence/featured-studies/feature/.
Forward-Looking Statements
All statements other than statements of historical facts
included in this press release that address activities, events or
developments that we expect, believe or anticipate will or may
occur in the future are forward-looking statements including, in
particular, the statements about our expectations for full fiscal
year GAAP and non-GAAP 2020 total, product, royalty and other
revenues, earnings per diluted share, gross margin, operating
margin, EBITDA, and estimated tax rate, and our long-term outlook;
demand for our products; anticipated revenue and earnings growth;
our financial condition, results of operations and business
generally; expectations regarding our ability to design and deliver
innovative new noninvasive technologies and reduce the cost of
care; and demand for our technologies. These forward-looking
statements are based on management’s current expectations and
beliefs and are subject to uncertainties and factors, all of which
are difficult to predict and many of which are beyond our control
and could cause actual results to differ materially and adversely
from those described in the forward-looking statements. These risks
include, but are not limited to, those related to: risks related to
the integration of the acquisition of the Connected Care assets
from NantHealth, Inc.; our dependence on Masimo SET® and Masimo
rainbow SET™ products and technologies for substantially all of our
revenue; any failure in protecting our intellectual property
exposure to competitors’ assertions of intellectual property
claims; the highly competitive nature of the markets in which we
sell our products and technologies; any failure to continue
developing innovative products and technologies; the lack of
acceptance of any of our current or future products and
technologies; obtaining regulatory approval of our current and
future products and technologies; the risk that the implementation
of our international realignment will not continue to produce
anticipated operational and financial benefits, including a
continued lower effective tax rate; the loss of our customers; the
failure to retain and recruit senior management; product liability
claims exposure; a failure to obtain expected returns from the
amount of intangible assets we have recorded; the maintenance of
our brand; the amount and type of equity awards that we may grant
to employees and service providers in the future; our ongoing
litigation and related matters; and other factors discussed in the
“Risk Factors” section of our most recent periodic reports filed
with the Securities and Exchange Commission (“SEC”), including our
most recent Form 10-K and Form 10-Q, all of which you may obtain
for free on the SEC’s website at www.sec.gov. Although we believe
that the expectations reflected in our forward-looking statements
are reasonable, we do not know whether our expectations will prove
correct. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
even if subsequently made available by us on our website or
otherwise. We do not undertake any obligation to update, amend or
clarify these forward-looking statements, whether as a result of
new information, future events or otherwise, except as may be
required under applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Patient
Outcome and Reducing Cost of Care... by Taking Noninvasive
Monitoring to New Sites and Applications, rainbow, SpHb, SpOC,
SpCO, SpMet, PVI and ORI are trademarks or registered trademarks of
Masimo Corporation.
MASIMO CORPORATION
CONDENSED CONSOLIDATED BALANCE
SHEETS
(unaudited, in
thousands)
December 28, 2019
December 29, 2018
ASSETS
Current assets
Cash and cash equivalents
$
567,687
$
552,490
Short-term investments
120,000
—
Trade accounts receivable, net of
allowance for doubtful accounts
132,433
109,629
Inventories
115,871
94,732
Other current assets
60,071
32,426
Total current assets
996,062
789,277
Lease receivable, noncurrent
49,936
—
Deferred costs and other contract
assets
16,214
122,906
Property and equipment, net
219,552
165,972
Intangible assets, net
27,251
27,924
Goodwill
22,350
23,297
Deferred tax assets
35,972
21,210
Other non-current assets
28,791
4,232
Total assets
$
1,396,128
$
1,154,818
LIABILITIES AND STOCKHOLDERS’
EQUITY
Current liabilities
Accounts payable
$
54,548
$
40,388
Accrued compensation
54,705
49,486
Deferred revenue and other
contract-related liabilities, current
25,939
32,054
Other current liabilities
37,027
24,627
Total current liabilities
172,219
146,555
Other non-current liabilities
56,035
39,198
Total liabilities
228,254
185,753
Commitments and contingencies
Stockholders’ equity:
Common stock
54
53
Treasury stock
(526,580
)
(489,026
)
Additional paid-in capital
600,624
533,164
Accumulated other comprehensive loss
(6,718
)
(6,199
)
Retained earnings
1,100,494
931,073
Total stockholders’ equity
1,167,874
969,065
Total liabilities and stockholders’
equity
$
1,396,128
$
1,154,818
MASIMO CORPORATION
CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS
(unaudited, in thousands,
except per share amounts)
Quarter Ended
Year Ended
December 28, 2019
December 29, 2018
December 28, 2019
December 29, 2018
Revenue:
Product
$
247,434
$
221,413
$
936,408
$
829,874
Royalty and other revenue
76
1,719
1,429
28,415
Total revenue
247,510
223,132
937,837
858,289
Cost of goods sold
80,587
74,801
308,665
283,397
Gross profit
166,923
148,331
629,172
574,892
Operating expenses:
Selling, general and administrative
81,943
73,713
314,661
285,417
Research and development
23,423
20,787
93,295
81,006
Litigation settlement, award and/or
defense costs
—
(75
)
—
425
Total operating expenses
105,366
94,425
407,956
366,848
Operating income
61,557
53,906
221,216
208,044
Non-operating income
2,812
1,652
12,950
5,732
Income before provision for income
taxes
64,369
55,558
234,166
213,776
Provision for income taxes
11,448
8,624
37,950
20,233
Net income
$
52,921
$
46,934
$
196,216
$
193,543
Other comprehensive gain (loss), net of
tax:
Foreign currency translation gains
(losses)
1,076
(382
)
(519
)
(3,258
)
Total comprehensive income
$
53,997
$
46,552
$
195,697
$
190,285
Net income per share:
Basic
$
0.99
$
0.88
$
3.67
$
3.70
Diluted
$
0.92
$
0.83
$
3.44
$
3.45
Weighted-average shares used in per share
calculations:
Basic
53,633
53,043
53,434
52,296
Diluted
57,267
56,449
57,100
56,039
The following table presents details of the stock-based
compensation expense that is included in each functional line item
in the condensed consolidated statements of operations (in
thousands):
Quarter Ended
Year Ended
December 28, 2019
December 29, 2018
December 28, 2019
December 29, 2018
Cost of goods sold
$
106
$
94
$
445
$
334
Selling, general and administrative
7,417
6,081
30,450
21,391
Research and development
2,067
1,547
8,340
5,692
Total
$
9,590
$
7,722
$
39,235
$
27,417
MASIMO CORPORATION
CONDENSED CONSOLIDATED
STATEMENTS OF CASH FLOWS
(unaudited, in
thousands)
Year Ended
December 28, 2019
December 29, 2018
Cash flows from operating
activities:
Net income
$
196,216
$
193,543
Adjustments to reconcile net income to net
cash provided by operating activities:
Depreciation and amortization
23,487
21,127
Stock-based compensation
39,233
27,417
Loss on disposal of equipment, intangibles
and other assets
357
949
Provision (benefit) for doubtful
accounts
687
(439
)
Benefit for amount due from former foreign
agent
—
(2,016
)
Benefit from deferred income taxes
(5,965
)
(8,274
)
Changes in operating assets and
liabilities:
(Increase) decrease in trade accounts
receivable
(23,580
)
10,826
Increase in inventories
(21,257
)
(1,885
)
(Increase) decrease in other current
assets
(8,536
)
3,843
Increase in lease receivable, net
(11,958
)
—
Decrease (increase) in deferred costs and
other contract assets
3,308
(17,935
)
(Increase) decrease in other non-current
assets
(226
)
407
Increase in accounts payable
9,934
5,211
Increase in accrued compensation
5,338
10,195
Increase in deferred revenue and other
contract-related liabilities
7,739
1,420
Increase (decrease) in income taxes
payable
4,079
(1,208
)
Increase in accrued liabilities
746
3,923
Increase (decrease) increase in other
non-current liabilities
2,038
(7,577
)
Net cash provided by operating
activities
221,640
239,527
Cash flows from investing
activities:
Purchases of short-term investments
(120,000
)
—
Purchases of property and equipment
(68,375
)
(17,126
)
Increase in intangible assets
(4,117
)
(5,557
)
Business acquisition, net of cash
acquired
—
(3,922
)
(Purchases of) proceeds from strategic
investments
(5,189
)
453
Net cash used in investing activities
(197,681
)
(26,152
)
Cash flows from financing
activities:
Proceeds from issuance of common stock
28,339
44,748
Repurchases of common stock
(37,555
)
(18,478
)
Other
(123
)
(490
)
Net cash provided by (used in) financing
activities
(9,339
)
25,780
Effect of foreign currency exchange rates
on cash
814
(1,997
)
Net increase in cash, cash equivalents and
restricted cash
15,434
237,158
Cash, cash equivalents and restricted cash
at beginning of period
552,641
315,483
Cash, cash equivalents and restricted cash
at end of period
$
568,075
$
552,641
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200219005938/en/
Investor Contact: Eli Kammerman (949) 297-7077
ekammerman@masimo.com
Media Contact: Evan Lamb (949) 396-3376
elamb@masimo.com
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Apr 2023 to Apr 2024